Delisting risk
Passage Bio
Winding down neurodegenerative gene therapies while pursuing a merger with Remix Therapeutics.
$4.52
After-hours close−0.04 (−0.88%)
At close$4.56(+5.31%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 55.40%1.78M sharesInsiders 0.37%11.9K sharesOther 44.23%1.42M shares
Shares outstanding 3.21M · Float 2.89M · 89.9% free float
Institutions13F, as of Mar 31, 2026
33 holders · 1.78M shares · 12 new positions · 18 increased · 4 reduced · 8 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| LYNX1 Capital Management LP | 623.7K | 19.41% | 0 | May 4, 2026 |
| Vestal Point Capital, LP | 305.0K | 9.49% | 0 | May 15, 2026 |
| Renaissance Technologies LLC | 133.6K | 4.16% | +24.5K | May 14, 2026 |
| Eversept Partners, LP | 131.6K | 4.10% | +5.4K | May 15, 2026 |
| Vanguard Capital Management LLC | 114.0K | 3.55% | +114.0Knew | May 15, 2026 |
| Yiheng Capital Management, L.P. | 86.1K | 2.68% | +51.8K | May 15, 2026 |
| Erste Asset Management GmbH | 85.3K | 2.65% | 0 | May 11, 2026 |
| Ikarian Capital, LLC | 68.1K | 2.12% | +68.1Knew | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Lynx1 Capital Management LPincl. Weston Nichols | 21.00% | 673.8K | 13D | Jul 2, 2026 ↗ |
| Ryan Wilderincl. Vestal Point Capital, LP | 9.90% | 13G | Nov 14, 2024 ↗ | |
| Baselake Partners, LP | 7.30% | 235.1K | 13G | Jun 25, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 10 percent owner | 673.8K | 20.97% | Jun 29, 2026 |
| Orbimed Advisors LLC | 10 percent owner | 303.3K | 9.44% | Jun 26, 2025 |
| William Chou | director, officer: PRESIDENT AND CEO | 6.5K | 0.20% | Jan 12, 2026 |
| Kathleen Borthwick | officer: CFO | 5.4K | 0.17% | Jan 12, 2026 |
4 ten-percent owners hold 1.16M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 16 people have not refiled in the last 18 months (709.0K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 25, 2026 | Lynx1 Capital Management LP10 percent owner | Purchase | 50,055 | $4.12 | 673,759 |
| Jan 8, 2026 | Kathleen Borthwickofficer: CFO | Sale | 2,062 | $18.44 | 5,402 |
| Jan 8, 2026 | William Choudirector, officer: PRESIDENT AND CEO | Sale | 4,076 | $18.44 | 6,524 |
| Sep 11, 2025 | Lynx1 Capital Management LP10 percent owner | Purchase | 325 | $6.96 | 592,021 |
| Sep 12, 2025 | Lynx1 Capital Management LP10 percent owner | Purchase | 19,783 | $6.99 | 611,804 |
| Sep 15, 2025 | Lynx1 Capital Management LP10 percent owner | Purchase | 11,900 | $6.99 | 623,704 |
CongressHouse and Senate disclosures
Not reported.